# STP938

Source: https://onco.cc/drugs/stp938/  
OnCo record `stp938` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

STP938 is a small-molecule inhibitor from Step Pharma, SAS, in registered phase 2 trials for non-Hodgkin lymphoma.

## Summary

STP938 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Step Pharma, SAS, in non-Hodgkin lymphoma. Described in the registry record as a small-molecule inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: STP938
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a small-molecule inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of STP938: https://clinicaltrials.gov/search?intr=STP938

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- trials: [A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas](https://onco.cc/trials/nct05463263/)

---
JSON: https://onco.cc/api/v1/entities/stp938.json